Literature DB >> 10197372

Longitudinal analysis of serum chemokine levels in the course of HIV-1 infection.

S Polo1, F Veglia, M S Malnati, C Gobbi, P Farci, R Raiteri, A Sinicco, P Lusso.   

Abstract

OBJECTIVES: To investigate the correlation between the serum levels of the CC-chemokines RANTES, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta, and the progression of HIV-1 disease.
DESIGN: Retrospective analysis of serial serum samples from HIV-1 seroconverters selected according to clinical outcome.
METHODS: Twenty-one patients, derived from a cohort recruited between 1985 and 1996 for a prospective study of the natural history of HIV infection, were analysed. All patients had at least one HIV-1-seronegative sample within 1 year prior to the first seropositive test and were followed longitudinally throughout the course of HIV-1 infection (mean follow-up, 73.5 months). Nine were rapid progressors (RP; patients who developed AIDS within 60 months of antibody seroconversion), seven were slow progressors (SP; patients who developed AIDS after 60 months), and five were long-term asymptomatic (LTA; patients with circulating CD4+ cells higher than 400 x 10(6)/l, no signs of HIV disease, no antiretroviral therapy for more than 96 months). A total of 339 serum samples was studied (mean, 16.1 per patient). The levels of RANTES, MIP-1alpha and MIP-1beta were measured by enzyme-linked immunosorbent assay and correlated with different immunological and clinical parameters.
RESULTS: Over the entire follow-up period, the geometric mean of serum RANTES was significantly higher in RP [68.6 ng/ml; 95% confidence interval (CI), 56.9-82.7] than in SP (23.7 ng/ml; 95% CI, 20.0-28.2; P < 0.001) and LTA (19.5 ng/ml; 95% CI, 15.5-24.5; P < 0.001). This difference was already significant during the early clinical stages, when patients had peripheral blood CD4+ cell counts still greater than 400 x 10(6)/l (P < 0.001). By contrast, the mean serum levels of MIP-1alpha and MIP-1beta did not differ significantly between the three study groups. Multivariate analysis using the Cox proportional hazard model demonstrated that the mean serum concentration of RANTES before the development of AIDS was independently associated with the time to AIDS (relative risk, 4.5; 95% CI, 1.1-18.2; P = 0.035). In patients with low versus high mean serum RANTES before the fall of CD4+ cells below 400 x 10(6)/l, the median AIDS-free time was 117.5 and 42.7 months, respectively (P = 0.037).
CONCLUSION: These data suggest that an elevation of serum RANTES predicts a rapid progression of the disease since the early stages of HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10197372     DOI: 10.1097/00002030-199903110-00002

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  15 in total

1.  Spontaneous and antigen-induced production of HIV-inhibitory beta-chemokines are associated with AIDS-free status.

Authors:  A Garzino-Demo; R B Moss; J B Margolick; F Cleghorn; A Sill; W A Blattner; F Cocchi; D J Carlo; A L DeVico; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

2.  Higher macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels from CD8+ T cells are associated with asymptomatic HIV-1 infection.

Authors:  F Cocchi; A L DeVico; R Yarchoan; R Redfield; F Cleghorn; W A Blattner; A Garzino-Demo; S Colombini-Hatch; D Margolis; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

3.  Highly active antiretroviral therapy and beta-chemokines.

Authors:  B Brichacek; M Bukrinsky
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

4.  Expression of chemokine genes in murine macrophages infected with Orientia tsutsugamushi.

Authors:  N H Cho; S Y Seong; M S Huh; T H Han; Y S Koh; M S Choi; I S Kim
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

5.  Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs.

Authors:  V S Torre; A J Marozsan; J L Albright; K R Collins; O Hartley; R E Offord; M E Quiñones-Mateu; E J Arts
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

Review 6.  HIV infection and pathogenesis: what about chemokines?

Authors:  R C Gallo; A Garzino-Demo; A L DeVico
Journal:  J Clin Immunol       Date:  1999-09       Impact factor: 8.317

7.  Intensive lifestyle modification reduces Lp-PLA2 in dyslipidemic HIV/HAART patients.

Authors:  Joshua S Wooten; Preethi Nambi; Baiba K Gillard; Henry J Pownall; Ivonne Coraza; Lynne W Scott; Vijay Nambi; Christie M Ballantyne; Ashok Balasubramanyam
Journal:  Med Sci Sports Exerc       Date:  2013-06       Impact factor: 5.411

8.  A microfluidic device for practical label-free CD4(+) T cell counting of HIV-infected subjects.

Authors:  Xuanhong Cheng; Daniel Irimia; Meredith Dixon; Kazuhiko Sekine; Utkan Demirci; Lee Zamir; Ronald G Tompkins; William Rodriguez; Mehmet Toner
Journal:  Lab Chip       Date:  2006-11-24       Impact factor: 6.799

Review 9.  Neutropenia during HIV infection: adverse consequences and remedies.

Authors:  Xin Shi; Matthew D Sims; Michel M Hanna; Ming Xie; Peter G Gulick; Yong-Hui Zheng; Marc D Basson; Ping Zhang
Journal:  Int Rev Immunol       Date:  2014-03-21       Impact factor: 5.311

10.  Stimulation of toll-like receptor 2 in mononuclear cells from HIV-infected patients induces chemokine responses: possible pathogenic consequences.

Authors:  L Heggelund; J K Damås; A Yndestad; A M Holm; F Mūller; E Lien; T Espevik; P Aukrust; S S Frøland
Journal:  Clin Exp Immunol       Date:  2004-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.